Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885891 | 0.90 | MAPK10 (0.65) | MAPK10MAPK9MAPK8ACHETACR3 | |
| SCHEMBL4018709 | 0.90 | MAPK10 (0.65) | MAPK10MAPK9MAPK8TACR3ALDH1A1 | |
| SCHEMBL2878429 | 0.88 | MAPK10 (0.62) | MAPK10MAPK9MAPK8ACHETACR3 | |
| SCHEMBL2886155 | 0.88 | MAPK10 (0.61) | MAPK10MAPK9MAPK8ACHETACR3 | |
| SCHEMBL2885492 | 0.86 | MAPK10 (0.59) | MAPK10MAPK9MAPK8TACR3ALDH1A1 | |
| SCHEMBL4023738 | 0.83 | MAPK10 (0.56) | MAPK10MAPK9MAPK8TACR3KDM4E | |
| SCHEMBL2881959 | 0.82 | MAPK10 (0.64) | MAPK10MAPK9MAPK8ALDH1A1 | |
| SCHEMBL2883388 | 0.82 | MAPK10 (0.58) | MAPK10MAPK9MAPK8ACHETACR3 | |
| SCHEMBL4024340 | 0.80 | MAPK10 (0.52) | MAPK10MAPK9MAPK8TACR3ALDH1A1 | |
| SCHEMBL4026422 | 0.80 | MAPK10 (0.62) | MAPK10MAPK9MAPK8ACHETACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | claimed |
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | claimed |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | claimed |
| EP-1696909-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | SERONO LAB (CH) | 2007-11-14 | — | — | EP | claimed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | claimed |
| US-7259162-B2 | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-21 | — | — | US | claimed |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-04-19 | — | — | US | claimed |
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | claimed |
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MERCK SERONO SA (CH) | 2003-08-28 | — | — | US | claimed |
| EP-1110957-A1 | Benzazole derivatives and their use as JNK modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-06-27 | — | — | EP | claimed |
| US-20140107116-A1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK SERONO SA (CH) | 2014-04-17 | — | — | US | disclosed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| EP-1450792-A1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA | Applied Research Systems ARS Holding N.V. (AN) | 2004-09-01 | — | — | EP | disclosed |
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | disclosed |
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MERCK SERONO SA (CH) | 2003-08-28 | — | — | US | disclosed |
| WO-2003047570-A1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-06-12 | — | — | WO | disclosed |
| EP-1110957-A1 | Benzazole derivatives and their use as JNK modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MAPK1, MAPK3, MAPKAPK2 | MAPK10 46/4885MAPK9 24/4885MAPK8 10/4885 |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | MAP3K20, MAPK3, MAPK10 | MAPK10 3/4885MAPK9 28/4885MAPK8 12/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | MAPK10 40/4885MAPK9 36/4885MAPK8 47/4885 |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | GPR119, GLS2, GLS | MAPK10 3255/4885MAPK9 4264/4885MAPK8 3132/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPK10 40/4885MAPK9 49/4885MAPK8 32/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPK10 40/4885MAPK9 49/4885MAPK8 32/4885 |
| US-20140107116-A1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | GPR119, GLS2, GLS | MAPK10 3544/4885MAPK9 4459/4885MAPK8 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.